MSCs Featured in Recent Journal Articles Adds to BioLife’s Growing Evidence Library

Mesenchymal Stem Cells have been the cell type of interest for the following articles recently entered into BioLife’s growing Evidence library. 1. Sutton, M. T., Kaur, S., Brown, K. S., Skiles, M. L., Folz, M. A., Caplan, A. I. and Bonfield, T. L.. (2018). Anti-Inflammatory Therapeutic Development and Optimization of Umbilical Cord Tissue Derived Mesenchymal…

Read More

BioLife Solutions Announces Third Quarter 2018 Financial Results

Revenue increases 79% to a record $5.3 million; achieves net income of $1.2 million On November 8, 2018,  BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, reported financial results and operational highlights for the three and nine months ended September 30, 2018. Revenue…

Read More

SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis

Temperature Sensitive Gene Therapy Protected by Cloud-Connected Smart Shipper and evo.is Cloud App for Real Time Distribution Visibility and Management On November 5, 2018, BioLife’s JV partner  SAVSU Technologies, a leading developer and supplier of precision cloud-connected thermal shipping containers and the most advanced cold chain visibility platform, announced that it is supplying its evo Smart…

Read More

BioPreservation Blog 8/8/2018

The number of applications for BioLife Solutions’ biopreservation reagents continues to grow, and we are pleased to highlight these newest citations: Habiel, D., Espindola, M., Coelho, A., & Hogaboam, C. Modeling Idiopathic Pulmonary Fibrosis in Humanized SCID Mice. The American Journal of Pathology 2018 Apr; 188(4): 891-903. doi: 10.1016/j.ajpath.2017.12.020 Habiel et. al. provided detailed methods for the creation…

Read More

New CryoStor Citations and our Growing Evidence Library

BioLife maintains an EVIDENCE PAGE on our corporate website with links to presentations, journal articles, abstracts and posters. We currently have over 365 citations and counting! Evidence is searchable by titles and keywords; and provides a tremendous resource for researchers and clinicians looking for relevant information on cell type, variant of optimized biopreservation media (for example: CS5 or…

Read More

BioLife Biopreservation Evidence Resources + New Citations

BioLife maintains an evidence page on our corporate website at biolifesolutions.com with links to presentations, journal articles, abstracts and posters citing the biopreservation efficacy of CryoStor and HypoThermosol.  These citation “evidence” pieces total over 345 strong and is constantly growing! Individual evidence citations (journal articles, abstracts, and posters citing our products) are searchable by title and…

Read More

Casdin Capital to Become Shareholder in BioLife Solutions – Investment Firm to Purchase Shares from Existing Holder

On April 9, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, (“BioLife” or the “Company”), announced that Casdin Capital LLC, (“Casdin”) a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company’s second…

Read More

Pathologically expanded peripheral T helper cell subsets drives B cells in rheumatoid arthritis

Rao, Gurish, Marshall, Slowikowski, Fonseka, Liu, Donlin, Henderson, Wei, MizoGuchi, Teslovich, Weinblatt, Massarotti, Coblyn, Helfgott, Lee, Todd, Bykerk, Goodman, Pernis, Ivashkiv, Karlson, Nigrovic, Filer, Buckley, Lederer, Raychaudhuri, Brenner. Pathologically expanded peripheral T helper cell subsets drives B cells in rheumatoid arthritis. Nature 542, 110–114 (02 February 2017) doi:10.1038/nature20810

Read More